Pre-Surgical Combination Therapy Enhances Survival in Rare Thyroid Cancer Patients
Combining pembrolizumab with targeted therapies significantly improves survival and surgical resection rates in patients with aggressive BRAF-mutated anaplastic thyroid cancer.
A recent study from The University of Texas MD Anderson Cancer Center has demonstrated that a pre-surgical combination treatment involving pembrolizumab, dabrafenib, and trametinib significantly improves outcomes in patients with BRAF V600E-mutated anaplastic thyroid cancer (BRAFm-ATC). This Phase II multicenter trial revealed that adding immunotherapy to targeted therapies not only increased the likelihood of tumor resection, with 74% of patients able to undergo surgery compared to just 5% with previous treatments, but also extended overall survival from an average of 14.5 to 18 months.
Anaplastic thyroid cancer is known for its aggressive nature, often presenting with tumors that are difficult to remove surgically. The study’s lead investigator, Dr. Mark Zafereo, noted that traditional treatments offered limited benefits, typically extending survival by only a few months. In contrast, incorporating pembrolizumab, an immunotherapy agent, alongside dabrafenib and trametinib—which inhibit the mutant BRAF protein—enabled better disease control.
Patients enrolled in the study between September 2021 and January 2025 received a median of four therapy cycles before surgery, with 30 out of 40 patients undergoing tumor removal. The combination therapy also doubled the progression-free survival, from approximately 6.7 months to over a year, indicating a delay in cancer progression.
While side effects such as kidney injury, sepsis, and intestinal tear were observed, the results suggest that this approach could become a new standard of care for BRAFm-ATC, especially for patients with the specific BRAF mutation. The study’s limitations include its small size, lack of a control group, and limited follow-up duration.
This research underscores the potential of combining immunotherapy with targeted treatments to improve surgical outcomes and prolong survival in aggressive thyroid cancers. Further studies are needed to confirm these findings and establish long-term benefits.
Source: https://medicalxpress.com/news/2025-06-pre-surgical-combination-therapy-boosts.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
How Maternal Obesity Reprograms Liver Immune Cells and Affects Offspring's Metabolism
Maternal obesity can reprogram liver immune cells in offspring, increasing the risk of fatty liver disease and metabolic disorders. New research highlights how early immune cell changes influence long-term health and potential treatment targets.
Breakthrough Immunotherapy Shows Potential Against Aggressive T Cell Cancers
A new universal CAR-T cell immunotherapy has shown promising results in treating aggressive T cell cancers, with high remission rates and manageable side effects, potentially transforming future treatment options.
FDA Director Suggests Pregnancy and COVID Vaccination Decision Should Be Personal
U.S. health authorities have shifted their stance on COVID-19 vaccination during pregnancy, leaving the decision to women and their doctors amidst ongoing debates about safety and benefits.
Large Language Models Demonstrate Potential in Predicting Liver Cancer Treatment Outcomes
Emerging research reveals that large language models like GPT-4 can accurately predict liver cancer treatment responses, aiding personalized oncology care and decision-making.